Rami Komrokji, MD

Articles

First-Line Treatment Options for Lower-Risk MDS With Symptomatic Anemia

July 3rd 2023

Yazan Madanat, MD, details the available options for first-line treatment of patients with lower-risk MDS and symptomatic anemia.

Dr Komrokji on the Classification of Patients With Myelodysplastic Syndromes

June 26th 2023

Rami Komrokji, MD, discusses key findings from an expanded analysis of the classification of patients with myelodysplastic syndromes.

Risk Stratification of MDS

June 26th 2023

Amer Zeidan, MBBS, MHS, explains risk stratification in MDS, how the process has evolved over time, and the guidelines he typically follows.

Diagnosing Myelodysplastic Syndromes (MDS)

June 26th 2023

Hetty Carraway, MD, reviews how MDS is diagnosed and the common symptoms that patients who have MDS may present with.

Dr Komrokji on Ongoing Studies in Higher- and Lower-Risk MDS

June 21st 2023

Rami Komrokji, MD, discusses ongoing clinical trials in patients with higher- and lower-risk myelodysplastic syndromes.

Emerging Therapies for Lower-Risk MDS

February 24th 2023

Expert hematologic oncologists discuss updates from the ASH 2022 Annual Meeting on emerging therapies for lower-risk MDS.

Luspatercept in Lower-Risk MDS

February 24th 2023

Following the ASH 2022 Annual Meeting, experts in hematologic oncology review updated data for luspatercept in lower-risk MDS.

First- and Second-Line Treatment Options in Lower-Risk MDS

February 24th 2023

Hematologic oncology experts give an overview of first- and second-line treatment options for lower-risk myelodysplastic syndromes.

Closing Remarks on Advances and Future Directions in MF and MDS

February 15th 2023

Amer Zeidan, MBBS, and Rami Komrokji, MD, offer closing remarks on recent advances in MF and MDS, and look towards the future of treatment.

Remaining Unmet Needs and Additional Ongoing Trials in MF

February 8th 2023

Dr Komrokji summarizes the remaining unmet needs in the treatment of MF, including suboptimal responses to JAK2 inhibitors, and comments on data from ongoing trials that may address these needs.

Myelofibrosis: Treatment Landscape and Recent Data Updates on JAK2 Inhibitors

February 8th 2023

A comprehensive review of the treatment landscape for myelofibrosis (MF) and recent ASCO and ASH data updates on JAK2 inhibitors.

Data on Emerging Therapies for Treatment of Higher-Risk MDS

February 1st 2023

Experts in hematology take a detailed look at new data on investigational therapies for higher-risk MDS, including the STIMULUS-MDS1 trial on sabatolimab.

Oral Hypomethylating Agents in MDS: Data Updates

February 1st 2023

Amer Zeidan, MBBS, and Rami Komrokji, MD, discuss trial updates on oral hypomethylating agents, including data on dosing, for treatment of lower-risk MDS.

Trial Updates on Low-Dose Lenalidomide and Luspatercept

January 25th 2023

An overview of updates from the Sintra-REV trial of low-dose lenalidomide, and data from COMMANDS, MEDALIST, and real-world studies on luspatercept.

IMerge: Updated Safety and Efficacy Data on Imetelstat for Lower-Risk MDS

January 25th 2023

Hematology experts highlight recent data updates from the IMerge trial on the telomerase inhibitor imetelstat, which is being studied for lower-risk MDS.

Tools for Risk Stratification and Prognosis in MDS

January 18th 2023

Uwe Platzbecker, MD introduces models commonly used to determine risk status and prognosis, and inform treatment decisions, for patients with MDS.

MDS: Typical Patient Presentation, Diagnostic Process, and Evolving Terminology

January 18th 2023

Moderator Rami Komrokji, MD, introduces the panel and invites expert pathologist Sanam Loghavi, MD to lead a discussion on the typical patient presentation and diagnostic process in MDS, which was recently renamed as ‘myelodysplastic neoplasms’ in the 2022 5th edition of the World Health Organization (WHO) classification of the disease state.

IPSS-M and IPSS-R Tools for Risk Stratification of MDS

January 18th 2023

Amer Zeidan, MBBS, and Rami Komrokji, MD, compare the available IPSS-M and IPSS-R tools for stratifying risk and assessing prognosis in MDS.

Classification Systems for MDS

January 18th 2023

Distinguished experts in hematology discuss the WHO and ICC classification systems for myelodysplastic syndromes (MDS), including recent WHO updates.

The Future of Myeloproliferative Neoplasm Treatment

August 24th 2022

The panelists conclude their discussion by highlighting investigational agents to look forward to.